Capstone Holding Corp. lowers convertible note conversion price to $1.00
Investing.com - Piper Sandler raised its price target on Adeptus Biotechnologies Corp. (NASDAQ:ADPT) to $15.00 from $13.00 on Wednesday, while maintaining an Overweight rating on the stock. The company, currently valued at $1.73 billion, has seen its shares surge 139.7% over the past year, with an impressive 84.32% gain year-to-date.
The research firm cited significant volume acceleration in the company’s MRD (Minimal Residual Disease) business, suggesting a sustainable 30% revenue growth rate for multiple quarters ahead. This outlook builds on the company’s current revenue growth of 21.6% and impressive gross margin of 70.07%. Piper Sandler identified EMR (Electronic Medical (TASE:BLWV) Record) integrations as a key driver expected to gain further traction.
The firm highlighted that ADPT has achieved cash flow break-even in its MRD business segment, demonstrating disciplined execution and financial management. With a healthy current ratio of 2.84, Piper Sandler expects the company to reach total business cash flow break-even next year. According to InvestingPro analysis, while the company maintains strong liquidity, analysts don’t anticipate profitability this year.
Continued ASP (Average Selling Price) expansion was also noted as a factor positioning Adeptus Biotechnologies to drive revenue growth in the top quartile of Piper Sandler’s coverage group. Get deeper insights into ADPT’s growth potential with InvestingPro, which offers exclusive financial health scores and 8 additional ProTips for informed investment decisions.
Piper Sandler designated Adeptus Biotechnologies as a "Top Pick" in its coverage universe, citing a clear path to profitability and accelerating growth as primary factors behind the increased price target. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading above its intrinsic value, suggesting investors should carefully consider their entry points.
In other recent news, Adeptus Biotechnologies has reported its second-quarter 2025 earnings, surpassing expectations with a revenue of $58.9 million, marking a 36% increase from the previous year. The company’s earnings per share (EPS) were reported at -$0.17, beating the forecasted -$0.24. Following these results, BTIG raised its price target for Adeptus Biotechnologies to $14 from $13, maintaining a Buy rating. BTIG noted the company’s strong second-quarter performance, highlighting its achievement of adjusted EBITDA positivity in its core MRD business ahead of schedule. Similarly, Morgan Stanley (NYSE:MS) increased its price target to $11 from $9, maintaining an Equalweight rating. Morgan Stanley attributed this adjustment to the company’s continued momentum in clonoSEQ volume and average selling price. These developments reflect a positive outlook from analysts regarding Adeptus Biotechnologies’ recent performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.